HCAT HEALTH CATALYST INC revenue, earnings and financials

For the quarter ended June 30, 2026, HEALTH CATALYST INC reported revenue of $70.5M (down 12.7% from a year earlier), net income of −$40.5M and diluted EPS of −$0.55; over the last four quarters revenue was $292M and net income −$265M; for the fiscal year ended December 2025 revenue was $311M, up 1.5% on the year before.

HCAT annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $311M, gross profit n/a, operating income −$161M, net income −$178M (margin -57.2%), EPS −$2.55
• Fiscal year ended Dec 2024: revenue $307M, gross profit n/a, operating income −$69.8M, net income −$69.5M (margin -22.7%), EPS −$1.15
• Fiscal year ended Dec 2023: revenue $296M, gross profit n/a, operating income −$127M, net income −$118M (margin -39.9%), EPS −$2.09
• Fiscal year ended Dec 2022: revenue $276M, gross profit n/a, operating income −$140M, net income −$137M (margin -49.7%), EPS −$2.63
• Fiscal year ended Dec 2021: revenue $242M, gross profit n/a, operating income −$144M, net income −$153M (margin -63.3%), EPS −$3.23

HCAT quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $70.5M (down 12.7% year over year), net income −$40.5M, EPS −$0.55
• Quarter ended Mar 31, 2026: revenue $70.8M (down 10.9% year over year), net income −$111M, EPS −$1.53
• Quarter ended Dec 31, 2025 (from the annual report): revenue $74.7M (down 6.2% year over year), net income −$91.0M, EPS −$1.29
• Quarter ended Sep 30, 2025: revenue $76.3M (down 0.0% year over year), net income −$22.2M, EPS −$0.32
• Quarter ended Jun 30, 2025: revenue $80.7M (up 6.3% year over year), net income −$41.0M, EPS −$0.59
• Quarter ended Mar 31, 2025: revenue $79.4M (up 6.3% year over year), net income −$23.7M, EPS −$0.35
• Quarter ended Dec 31, 2024 (from the annual report): revenue $79.6M (up 6.0% year over year), net income −$20.7M, EPS −$0.33
• Quarter ended Sep 30, 2024: revenue $76.4M (up 3.5% year over year), net income −$14.7M, EPS −$0.24
• Quarter ended Jun 30, 2024: revenue $75.9M (up 3.7% year over year), net income −$13.5M, EPS −$0.23
• Quarter ended Mar 31, 2024: revenue $74.7M (up 1.2% year over year), net income −$20.6M, EPS −$0.35
• Quarter ended Dec 31, 2023 (from the annual report): revenue $75.1M (up 8.6% year over year), net income −$30.3M, EPS −$0.52
• Quarter ended Sep 30, 2023: revenue $73.8M (up 7.9% year over year), net income −$22.0M, EPS −$0.39
• Quarter ended Jun 30, 2023: revenue $73.2M (up 3.7% year over year), net income −$32.6M, EPS −$0.58
• Quarter ended Mar 31, 2023: revenue $73.9M (up 8.5% year over year), net income −$33.2M, EPS −$0.60
• Quarter ended Dec 31, 2022 (from the annual report): revenue $69.2M (up 6.9% year over year), net income −$35.8M, EPS −$0.63
• Quarter ended Sep 30, 2022: revenue $68.4M (up 10.7% year over year), net income −$45.7M, EPS −$0.84
• Quarter ended Jun 30, 2022: revenue $70.6M (up 18.5% year over year), net income −$33.4M, EPS −$0.62
• Quarter ended Mar 31, 2022: revenue $68.1M (up 21.9% year over year), net income −$22.5M, EPS −$0.54
• Quarter ended Dec 31, 2021 (from the annual report): revenue $64.7M, net income −$49.0M, EPS −$0.96
• Quarter ended Sep 30, 2021: revenue $61.7M, net income −$40.0M, EPS −$0.82

HCAT cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $731K, share buybacks $5.00M
• Fiscal year ended Dec 2024: operating cash flow $14.6M, share buybacks $0
• Fiscal year ended Dec 2023: operating cash flow −$33.1M, share buybacks $1.81M
• Fiscal year ended Dec 2022: operating cash flow −$35.3M, share buybacks $8.39M
• Fiscal year ended Dec 2021: operating cash flow −$23.1M, share buybacks $0

HCAT balance sheet

• Jun 30, 2026: cash $60.6M, total assets $359M, total liabilities $258M, shareholders' equity $101M, long-term debt $152M
• Mar 31, 2026: cash $59.9M, total assets $412M, total liabilities $274M, shareholders' equity $138M, long-term debt $152M
• Dec 31, 2025: cash $50.8M, total assets $503M, total liabilities $257M, shareholders' equity $246M, long-term debt $152M
• Sep 30, 2025: cash $40.3M, total assets $587M, total liabilities $255M, shareholders' equity $332M, long-term debt $152M
• Jun 30, 2025: cash $50.7M, total assets $616M, total liabilities $269M, shareholders' equity $348M, long-term debt $151M
• Mar 31, 2025: cash $342M, total assets $892M, total liabilities $515M, shareholders' equity $377M, long-term debt $151M
• Dec 31, 2024: cash $250M, total assets $859M, total liabilities $494M, shareholders' equity $365M, long-term debt $151M
• Sep 30, 2024: cash $328M, total assets $813M, total liabilities $458M, shareholders' equity $355M, long-term debt $115M

What is HCAT's revenue?

HEALTH CATALYST INC reported $292M of revenue over its last four quarters, through June 30, 2026.

Is HCAT profitable?

No. HEALTH CATALYST INC lost $265M over the last four quarters.

What is HCAT's EPS?

Diluted earnings per share over the last four quarters were −$3.69; −$0.55 in the latest quarter.

HCAT ownership and insider trades · All stocks